Clinical trial
A Phase 2 Clinical Trial Comparing the Efficacy and Safety of Once-weekly GZR4 Injection Versus Once-daily Insulin Degludec in Subjects with Type 2 Diabetes Mellitus on OAD Therapy or OAD Therapy in Combination with Basal Insulin
NCT06202079 is registered in ClinicalTrials.gov with Gan and Lee Pharmaceuticals, USA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Clinical Trial Comparing the Efficacy and Safety of Once-weekly GZR4 Injection Versus Once-daily Insulin Degludec in Subjects with Type 2 Diabetes Mellitus on OAD Therapy or OAD Therapy in Combination with Basal Insulin
- Lead sponsor
- Gan and Lee Pharmaceuticals, USA
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 11, 2023
- Completion date
- August 8, 2024
- Enrollment
- 179 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.